The effect of water solubility of solutes on their flux through human skin in vitro:: A prodrug database integrated into the extended Flynn database

被引:16
作者
Juntunen, Juha [1 ,2 ]
Majumdar, Susruta [3 ]
Sloan, Kenneth B. [1 ]
机构
[1] Univ Florida, Dept Med Chem, Gainesville, FL 32610 USA
[2] Univ Kuopio, Dept Pharmaceut Chem, FIN-70211 Kuopio, Finland
[3] Mem Sloan Kettering Canc Ctr, Lab Mol Pharmacol & Chem, New York, NY 10021 USA
关键词
prodrugs; water solubility; octanol solubility; Roberts-Sloan equation; hydrolysis;
D O I
10.1016/j.ijpharm.2007.09.034
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A database (n=50) consisting of values of solubility in water, S-AQ, solubility in octanol, S-OCT, molecular weight, MW, and maximum flux based on the delivery of total species containing a parent drug by its prodrugs through human skin in vitro from water has been integrated into the extended Flynn database (n=114). In addition, data for two more recent contributions (n=8) and one (n=7) contribution that was overlooked for inclusion in the extended Flynn database were added to the prodrug database, as well as the data for the parent drugs (n=6), to give n=71 and n=185 for the total integrated database. This integrated database was fit to five equations where the independent variable was SAQ, SOCT or MW alone or were combinations of S-OCT and MW (Kasting-Smith-Cooper, KSC model) or SOCT, SAQ and MW (Roberts-Sloan, RS model). The RS equation gave the best fit: log J(MAQ) = -2.506 + 0.538 log S-OCT + 0.462 log S-AQ -0.00402MW, r(2) = 0.839, S.D. = 0.423 and the residual (Delta log J(MAQ)) was 0.474 log units. Integration of a substantial number of prodrugs into the extended Flynn database did not change the dependence of J(MAQ) on a balance of S-AQ and S-OCT. No trend in the effect of the prodrug being more or less water soluble than its parent drug on over- or underpredicting flux (+/-Delta'log J(MAQ)) by the RS model was found. Thus optimization of the S-AQ of a prodrug in its design, as well as the design of new drugs, is indicated. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:92 / 103
页数:12
相关论文
共 30 条
[1]   Evaluation of stereoselective transdermal transport and concurrent cutaneous hydrolysis of several ester prodrugs of propranolol: Mechanism of stereoselective permeation [J].
Ahmed, S ;
Imai, T ;
Otagiri, M .
PHARMACEUTICAL RESEARCH, 1996, 13 (10) :1524-1529
[2]   Effects of skin metabolism on percutaneous penetration of lipophilic drugs [J].
Bando, H ;
Mohri, S ;
Yamashita, F ;
Takakura, Y ;
HAshida, M .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (06) :759-761
[3]   ENHANCED DELIVERY OF NALIDIXIC-ACID THROUGH HUMAN-SKIN VIA ACYLOXYMETHYL ESTER PRODRUGS [J].
BUNDGAARD, H ;
MORK, N ;
HOELGAARD, A .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1989, 55 (2-3) :91-97
[4]  
Dal Pozzo A., 1996, International Journal of Cosmetic Science, V18, P57, DOI 10.1111/j.1467-2494.1996.tb00135.x
[5]   UTILIZATION OF PRODRUGS TO ENHANCE THE TRANSDERMAL ABSORPTION OF MORPHINE [J].
DRUSTRUP, J ;
FULLERTON, A ;
CHRISTRUP, L ;
BUNDGAARD, H .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1991, 71 (1-2) :105-116
[6]   Physico-chemical determinants of dermal drug delivery: effects of the number and substitution pattern of polar groups [J].
du Plessis, J ;
Pugh, WJ ;
Judefeind, A ;
Hadgraft, J .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 16 (03) :107-112
[7]   The effect of hydrogen bonding on diffusion across model membranes: consideration of the number of H-bonding groups [J].
Du Plessis, J ;
Pugh, WJ ;
Judefeind, A ;
Hadgraft, J .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 13 (02) :135-141
[8]  
Flynn G., 1990, PRINCIPLES ROUTE TO, P93
[9]   Percutaneous delivery of carbamazepine and selected N-alkyl and N-hydroxyalkyl analogues [J].
Fourie, L ;
Breytenbach, JC ;
Du Plessis, J ;
Goosen, C ;
Swart, H ;
Hadgraft, J .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 279 (1-2) :59-66
[10]   Synthesis and transdermal properties of acetylsalicylic acid and selected esters [J].
Gerber, M ;
Breytenbach, JC ;
Hadgraft, J ;
du Plessis, J .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 310 (1-2) :31-36